Simulations Plus Signs Additional Collaboration Agreement
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation
and modeling software for pharmaceutical discovery and development,
announced today that it has signed a collaboration agreement with a
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a collaboration agreement with a top-5 pharmaceutical company to add a transdermal and subcutaneous dosing model within its industry gold standard GastroPlus™ simulation software program. Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “We’re very pleased to announce this second funded collaboration this month, which will extend and enhance the GastroPlus simulation model for drug dosing via transdermal and subcutaneous dosing through a variety of dosage forms. Our funded collaborations enable us to extend the competitive advantage of GastroPlus without the need for Simulations Plus to fund the development directly. These will include skin creams, patches, and microneedles for dosing through the skin, as well as injections below the skin in the subcutaneous model.” John DiBella, vice president of marketing and sales for Simulations Plus, added, “We continue to expand the capabilities of GastroPlus, extending our competitive advantage, as evidenced by this second new funded collaboration. We expect this agreement to augment our steady growth in software licensing revenues, and make up for the lack of collaboration funding in recent quarters when compared to their year-previous quarters, as well as adding to the revenue growth we’ve experienced.” About Simulations Plus, Inc. Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com. Follow Us on TwitterSafe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.